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In this issue of the BJC, Sir Richard Doll and colleagues from
Oxford present findings from the 50 years of follow-up of British
doctors in relation to cancer risk (Doll et al, 2005). There are many
important aspects surrounding this article, some of which deserve
wider and deep reflection.
This has been a study that was completely innovative and
ingenious in its construction and remarkable in the perseverance
of its follow-up. When Richard Doll and Austin Bradford-Hill
undertook this cohort study, they probably did not realise that
they were setting a new paradigm for modern epidemiology, and
choosing to do such a study among doctors was quite ingenious.
Which group would be able to be followed to death by a variety of
sources including via the Medical Register?
The initial results (Doll and Hill, 1954; Doll and Peto, 1976) were
highly significant and of great value in identifying a new and
significant cancer risk, but the true worth of this study increased as
follow-up increased and the flow of new information emerged.
During the course of the follow-up, and in particular in the reports
after 40 years follow-up (Doll et al, 1994) and 50 years of follow-up
(Doll et al, 2004), the real impact of tobacco smoking on a wide
variety of diseases and life expectancy itself was fully revealed. Half
of the smokers die from a tobacco-related disease and half of these
deaths occur in middle age. The impact of these deaths on the loss
of nonsmokers life expectancy is enormous. Stopping smoking at
any age is effective in reducing the loss of nonsmokers life
expectancy, although this lessens off as age at quitting increases.
The comparison presented here (Doll et al, 2005) is in many
respects unique. Here, we have the opportunity to observe what
really happens over a long period among those who are exposed to
a carcinogenic risk and to compare it with a descriptive analysis of
all the available published, epidemiological and mechanistic
evidence.
The International Agency for Research on Cancer (IARC)
prepared a Monograph on Tobacco Smoking initially in 1986
(International Agency for Research on Cancer, 1986). When this
was recently revised (International Agency for Research on Cancer,
2004a) in 2004, there was new information available to increase the
numbers of cancer types deemed to be causally related to tobacco
smoking (Figure 1). In 11 of 13 cancer types considered by IARC to
be causally related to tobacco smoking, and which could be
identified on death certificates, Doll and colleagues found them to
be significantly related to smoking (Doll et al, 2005). For the two
remaining sites (nasopharynx, nose and nasal cavity), deaths in the
doctors’ cohort were sparse, although there was a suggestion that
there could well be an association (Doll et al, 2005).
In the IARC Monograph (2004a), colorectal cancer and prostate
cancer are the two types of cancer that fell between the two classes
of sufficient evidence of carcinogenicity and evidence suggesting
lack of carcinogenicity. For colorectal cancer, the Working Group
considered that bias and confounding could not be ruled out as
alternative explanations of the associations seen, while for prostate
cancer, it was felt that the available studies were not mutually
consistent in showing a positive association. Doll et al (2005)
found a potential association restricted to a subgroup of colorectal
cancers and no association for prostate cancer. Importantly, there
is little evidence of increased site-specific cancer risk for those
forms of cancer considered by the IARC Working Group not to be
associated with tobacco smoking.
These findings are an excellent example of the robustness of the
procedure which the IARC Monographs programme employs to
evaluate carcinogenicity of a chemical, biological, physical or
lifestyle exposure (Cogliano et al, 2004a). An International
Working Group that includes the best experts in the field, not
tainted by conflicts of interest, reaches their conclusion after
thoroughly reviewing all the published database.
The cancer sites identified as causally associated with tobacco
smoking in the previous Monograph on tobacco smoking almost
20 years ago (International Agency for Research on Cancer, 1986)
were all confirmed in IARC’s (2004a) re-evaluation. As many more
studies were available for the current evaluation, several cancer
sites were added to the list of tobacco-associated cancers (Figure 1).
IARC has now just completed within the Monographs pro-
gramme a re-examination of all main forms of tobacco, and all of
them have been clearly shown to be carcinogenic to humans:
tobacco smoking (Figure 1) and involuntary smoking (lung) and
the use of betel quid with tobacco (oral cavity, pharynx and
oesophagus) (International Agency for Research on Cancer, 2004b)
as well as the use of smokeless tobacco (oral and pancreatic
cancer) (Cogliano et al, 2004b).
Tobacco is the best-identified human carcinogen and is
carcinogenic in all its forms of use. It is clear, and has been for
several years now, that the effect of tobacco on cancer risk, and
indeed on overall mortality, is far in excess of any other common
risk factor or treatment effect. Information nowadays taken for
granted (half of smokers die of a smoking-related disease, half of
these deaths are in middle age, each smoking-related death in
middle age loses over 20 years of a nonsmokers life expectancy,
there are over 20 fatal diseases causally linked to cigarette
smoking, even if a smoker stops smoking in middle age he starts
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particular Sir Richard Peto) and from the extensive follow-up of
the British doctors’ cohort.
The early findings from Doll’s group (Doll and Hill, 1952,
1954), which clearly identified smoking as a human carcinogen,
had a large influence in the great decline in the prevalence of
cigarette smoking, which took place in the United Kingdom since
the 1950s, and in the United States and many other countries
shortly thereafter (Peto et al, 2000). This has undoubtedly
postponed many deaths in the United Kingdom and in many
other parts of the world and has led to millions of men (and
women) having several years of increased life expectancy. While
such a contribution from any one research group is outstanding,
that this group has made major contributions in other major
disease areas including radiation and cancer, asbestos and other
occupational carcinogens, oral contraceptives and disease, treat-
ment of early breast cancer, immediate treatment of myocardial
infarction and aspirin and myocardial infarction is unique and
remarkable.
Unsurprisingly, Sir Richard Doll and Sir Richard Peto have
received many awards and widespread recognition for their
contribution to public health. Such recognition is well deserved
even though such statistics-based contributions may well be
undervalued (Breslow, 2003). Apart from DA Henderson (who
directed the World Health Organization’s global smallpox
eradication campaign (1966–1977) and helped to initiate WHO’s
global programme of immunisation in 1974), it is difficult to
identify a greater contribution to public health in recent times.
They really made a difference.
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Figure 1 Types of cancer considered to be causally related to tobacco
smoking in successive IARC monograph evaluations (International Agency
for Research on Cancer, 1986, 2004a).
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